Co-Diagnostics

Co-Diagnostics Days Payable Outstanding

The Days Payable Outstanding (DPO) of Co-Diagnostics (CODX) as of Nov 20, 2026 is 3,082.84. In the previous year, Days Payable Outstanding (DPO) was 1,203.46 — a change of 156.17% (higher).

Days Payable Outstanding

3,082.84

YoY

156.17%

Last updated:

Days Payable Outstanding (DPO) of Co-Diagnostics is 2025 3,082.84 . Days Payable Outstanding (DPO) of Co-Diagnostics was 2024 1,203.46 . It decreases by 156.17% higher compared to the previous year.

The Co-Diagnostics Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2018
5,789.90 USD
Jan 1, 2019
19.35 USD
Jan 1, 2020
13.16 USD
Jan 1, 2021
19.16 USD
Jan 1, 2022
63.42 USD
Jan 1, 2023
129.27 USD
Jan 1, 2024
1,203.46 USD
Jan 1, 2025
3,082.84 USD
The Co-Diagnostics Days Payable Outstanding history
YEARDays Payable OutstandingYoY
3,082.84+156.17%
1,203.46+831.00%
129.27+103.84%
63.42+231.03%
19.16+45.54%
13.16-31.96%
19.35-99.67%
5,789.90-88.26%
49,334.22+4,729.10%
1,021.60+22.14%
836.41—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Co-Diagnostics Stock analysis

What does Co-Diagnostics do? Co-Diagnostics, Inc. develops and sells diagnostic tests using proprietary reagents and a test design system for diseases and pathogens including tuberculosis, drug-resistant tuberculosis, hepatitis B and C, malaria, dengue, HIV, and Zika virus. The company also markets self-contained lab systems (MDx devices) from other manufacturers. Its products are sold to laboratories and healthcare providers for molecular testing of organisms and genetic diseases, automating complex procedures in test development and administration. The firm generates revenue through the sale of diagnostic reagents, validated tests, and MDx devices. The company's diagnostic technology focuses on nucleic acid detection and analysis, enabling molecular testing for various pathogens and genetic conditions. Its proprietary system allows for the design and validation of tests in-house, which are then marketed to healthcare institutions. Revenue streams include reagent sales, test kits, and equipment from partner manufacturers. Co-Diagnostics, Inc. targets laboratories and healthcare providers as key customers for its diagnostic solutions. The firm's products are designed to streamline molecular testing processes, reducing the complexity of traditional methods. This approach supports the company's revenue model based on direct sales of its proprietary tests and complementary equipment. Co-Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Co-Diagnostics stock

Days Payable Outstanding (DPO) of Co-Diagnostics is 3,082.84 in 2025.

Days Payable Outstanding (DPO) of Co-Diagnostics changed from 1,203.46 to 3,082.84, representing a 156.17% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) Co-Diagnostics since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s Co-Diagnostics with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Co-Diagnostics

All Key Metrics — Co-Diagnostics